Kailera Therapeutics (KLRA)
Develops injectable and oral obesity medicines outside Greater China under a Hengrui license.
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027 Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the second quarter ended June 30, 2026, and provided a summary of recent business highlights.
Why Is Kailera Therapeutics Stock Falling Tuesday?
Kailera Therapeutics Inc. (NASDAQ:KLRA) stock fell about 9% on Tuesday after the company reported positive topline results from two Phase 3 trials of its oral GLP-1 drug candidate HRS-7535/KAI-7535 in China.
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Ka
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 program Reported positive topline clinical data from three trials conducted by our partner Hengrui in China, including new topline data from Phase 3 trial of oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes, and first-in-human topline data from Phase 1 trial for injectable tri-agonist HRS-4729 (KAI-4729) Cash on hand, including IPO proceeds, is expected to fund operations into mid-2028 WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the first quarter ended March 31, 2026, and provided a summary of recent business highlights.
Is Kailera Therapeutics a Buy After Its Sizzling IPO?
There's a new challenger to the more established players in the weight-loss drug space.
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
On Tuesday, William Blair initiated coverage on Kailera Therapeutics Inc. (NASDAQ:KLRA), the latest entrant in the fast-growing weight-loss drug market.
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–8, 2026 in New Orleans, Louisiana.
A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million
Kailera Therapeutics, a clinical-stage biotech focused on obesity treatments, just reported a notable insider buy in recent SEC filings.
Rtw Investments, Lp Acquires 500,000 Shares of Kailera Therapeutics (NASDAQ:KLRA) Stock
Kailera Therapeutics, Inc. (NASDAQ: KLRA - Get Free Report) major shareholder Rtw Investments, Lp purchased 500,000 shares of the business's stock in a transaction on Monday, April 20th. The shares were bought at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the acquisition, the insider owned 10,776,820 shares in the
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy
A company set up to develop Hengrui Pharma's weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the "NewCo" business model
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the closing of its initial public offering of 44,921,875 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 5,859,375 additional shares, at the initial public offering price of $16.00 per share.
Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race
On Thursday, Kailera Therapeutics Inc. (NASDAQ: KLRA) priced its initial public offering of 39.06 million shares at $16.00 per share, with gross proceeds of around $625 million.
Kailera Therapeutics Announces Pricing of Initial Public Offering
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share.
Kailera Therapeutics files for US IPO
Kailera Therapeutics has filed for a U.S. initial public offering, it said in a filing on Friday.